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Abstract
Infectious diseases caused by apicomplexan parasites remain a
global public health threat. The presence of multiple ligand-binding
sites in tubulin makes this protein an attractive target for anti-
parasite drug discovery. However, despite remarkable successes as
anti-cancer agents, the rational development of protozoan parasite-
specific tubulin drugs has been hindered by a lack of structural and
biochemical information on protozoan tubulins. Here, we present
atomic structures for a protozoan tubulin and microtubule and
delineate the architectures of apicomplexan tubulin drug-binding
sites. Based on this information, we rationally designed the
parasite-specific tubulin inhibitor parabulin and show that it inhi-
bits growth of parasites while displaying no effects on human cells.
Our work presents for the first time the rational design of a species-
specific tubulin drug providing a framework to exploit structural dif-
ferences between human and protozoa tubulin variants enabling
the development of much-needed, novel parasite inhibitors.
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Introduction
Apicomplexan parasites represent a large group of obligate intracellu-
lar pathogens that cause medically and agriculturally significant
human and animal diseases including malaria, toxoplasmosis,
babesiosis, cryptosporidiosis, and eimeriosis. The recent emergence
of multiple drug-resistant parasites is a serious threat to global health
security and thus necessitates the urgent development of drugs target-
ing novel parasite proteins and pathways (Menard & Dondorp, 2017;
Uwimana et al, 2020). Successful parasitism relies on the ability of
parasites to rapidly invade host cells, to evade the host immune
response, and to maintain robust growth within host cells. The para-
site microtubule (MT) cytoskeleton plays a central role in the process
of parasite replication and it also constitutes a key component of the
parasite invasion machinery (reviewed in Morrissette (2015)).
MTs are assembled from ab-tubulin heterodimers and undergo
phases of growth and shrinkage, a property termed dynamic instabil-
ity (reviewed in Akhmanova and Steinmetz (2015)). MT-targeting
agents are among the most important drugs used in medical therapies
to combat cancer. They act by either stabilizing or destabilizing MTs
(Dumontet & Jordan, 2010). Recent advances in the structural charac-
terization of tubulin– and MT–agent complexes have led to the identi-
fication of six distinct drug-binding sites in mammalian tubulin
(reviewed in Steinmetz and Prota (2018)). Although tubulin is highly
conserved among eukaryotes, protozoan tubulins are much less
sensitive to mammalian MT-targeting agents such as colchicine (King
& Beams, 1940; Bejon et al, 1997; Morrissette & Sibley, 2002). Simi-
larly, dinitroaniline compounds disrupt specifically plant and proto-
zoan parasite MTs but not mammalian MTs (Fennell et al, 2008).
These observations imply that fine structural differences in the archi-
tecture of drug-binding sites between protozoan and mammalian
tubulin could be exploited to develop novel parasite-specific anti-
tubulin drugs. Additionally, by targeting tubulin—an essential protein
that contains multiple drug-binding sites—combination therapies that
engage distinct pockets at the same time could represent a unique
strategy to circumvent the development of drug resistance.
Results and Discussion
To analyze the entire spectrum of established, or any new putative
additional, drug-binding sites in apicomplexan tubulin, we need
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structural information on both the “straight”, assembled conforma-
tion of tubulin in MTs and the “curved” conformation of its free
form in solution (Knossow et al, 2020). As attempts to produce
recombinant apicomplexan tubulin similar to what has been
achieved for human tubulin (Ti et al, 2016) have proved unsuccess-
ful, we decided to isolate tubulin dimers from the free-living ciliate
Tetrahymena thermophila, as its tubulin is abundantly expressed
and nearly identical (87–95% identity) to apicomplexan tubulins.
Ciliates and apicomplexans both belong to the alveolate group (Dor-
rell et al, 2013), and their tubulins are sensitive to dinitroanilines
(Lyons-Abbott et al, 2010), suggesting that T. thermophila tubulin
can be used as a proxy to study the interaction of ligands with
apicomplexan tubulin.
Purified T. thermophila tubulin (Lyons-Abbott et al, 2010)
(Fig 1A) readily polymerized into MTs in vitro as revealed by cryo-
electron microscopy (Fig 1B). We used total internal reflection fluo-
rescence (TIRF) microscopy to assess T. thermophila MT dynamics
(Telley et al, 2011). When tested at a standard concentration range
used to observe bovine brain MT dynamics (10–15 µM tubulin),
many, long MTs filled the entire field of view (Appendix Fig S1).
However, MT dynamics could readily be observed and quantified
for T. thermophila tubulin at concentrations of less than 5 µM
(which is below the critical concentration for bovine brain tubulin
under these conditions, Fig 1C). T. thermophila MT growth rates
(Fig 1D) were much faster compared to mammalian brain tubulin
(growth rate of 2 lm-min1 at 5 lM for T. thermophila compared to
0.5 lm-min1 for B. taurus) but comparable to those observed with
C. elegans tubulin (Chaaban et al, 2018).
To obtain structural information on T. thermophila tubulin and
MTs, we employed X-ray crystallography and cryo-electron micro-
scopy, respectively. We solved the structures of T. thermophila ab-
tubulin in complex with DARPin1 (D1; (Pecqueur et al, 2012)) at
1.75 A resolution (Fig 1F, Appendix Table S1) and paclitaxel-
stabilized T. thermophila MTs at 3.3 A resolution (Fig 1E and
Appendix Fig S2 and Table S2). To assess structural differences
between protozoan and host mammalian tubulins, we also crystal-
lized and solved the structure of recombinant human a1b3-tubulin
in complex with D1 at 1.9 A resolution (Fig 1F and
AppendixTable S1). The overall structure of T. thermophila tubulin
is similar to that of human (RMSD of 0.49 A over the 751 Ca atoms
of curved ab-tubulin, and RMSD of 0.77 A over the 801 Ca atoms of
straight ab-tubulin) or yeast tubulin (Ayaz et al, 2014) (RMSD of
0.73 A over the 755 Ca atoms of curved ab-tubulin, and RMSD of
0.796 A over the 789 Ca atoms of straight ab-tubulin).
Next, we compared the details of all six known drug-binding
sites in mammalian tubulin (reviewed in (Steinmetz & Prota, 2018))
with the equivalent regions in T. thermophila tubulin to identify
structurally unique features of protozoan tubulin (Fig 2A) using the
three structures generated here as well as the published recombi-
nant human MT structure (Vemu et al, 2016). The residue composi-
tion of the maytansine, laulimalide/peloruside, and vinblastine sites
are identical between T. thermophila and human tubulin (Figs EV3
and EV4). In the case of the taxane and pironetin sites, we found dif-
ferences in one and three amino acid positions, respectively
(Figs 2A and EV1 and EV2). The most prominent differences
between T. thermophila and human tubulin were observed for the
colchicine site that is located at the a-b intra-tubulin dimer interface
(Ravelli et al, 2004). It is formed by residues of helices H7 and H8,
loop T7, and strands S8 and S9 of b-tubulin and is completed by
residues of loop T5 of a-tubulin (Fig 2A). Tubulin dimers undergo a
“curved-to-straight” conformational change upon incorporation into
MTs, which requires rotational movements of strands S8 and S9 and
a translation of helix H7 in both tubulin monomers and leads to a
loss of the colchicine site (Ravelli et al, 2004; Wang et al, 2016;
Sharma et al, 2017). Ligands that bind to the colchicine site block
this conformational change and thus “freeze” tubulin in the MT
incompatible, curved conformation (Fig EV3).
The structure of the colchicine site of mammalian tubulin is exten-
sively characterized and contains three distinct zones: a central zone
and two flanking accessory zones (Massarotti et al, 2012). We
modeled the mammalian tubulin-bound conformation of colchicine
(Prota et al, 2014) in the context of the T. thermophila tubulin and
compared it to human tubulin (see methods). Notably, the residues
of human tubulin of the colchicine site among different human tubu-
lin isoforms are overall largely conserved (AppendixFigs S3 and S4).
However, as shown in Fig 2A and Fig EV2A, we observed amino acid
differences in all the three zones of the T. thermophila colchicine site
compared to all human isoforms. To assess whether such differences
can affect the drug sensitivity at the organism level, we performed
turbidity-based T. thermophila growth-inhibition assays in the pres-
ence of the three well-characterized colchicine-site ligands colchicine,
combretastatin A4 (CA4), and plinabulin, all of which are known to
bind at distinct zones of the colchicine site (Appendix Fig S5A). As
shown in Appendix Fig S5B, CA4 showed a partial T. thermophila
growth inhibition activity in between the ones of plinabulin (stron-
gest effect) and colchicine (no effect). We decided to focus on CA4 as
a starting point for optimization as we reasoned that it has the best
chance to be further developed into an anti-parasite-specific agent.
CA4 is a well-known anti-cancer drug currently in several phase 3
clinical trials (Grisham et al, 2018). It binds at zones 1 and 2 of
mammalian tubulin with its 3,4,5-methoxy-substituted ring (ring A)
making interactions with residues bV238, bS/C241, bL242, bA250
(serine in protozoa), bL255, bA316 (serine in protozoa), bI318
(leucine in protozoa), and bI378 (valine in protozoa) in zone 2 of the
colchicine site, and its 3’-hydroxy-4’-methoxy-substituted ring (ring
B) making interactions with the zone 1 residues bN258, bK352,
bA316 (serine in protozoa), bM259 (leucine in protozoa), bN349, and
aT179 of the colchicine-site (Fig 2B) (Gaspari et al, 2017).
Based on structural modeling, we observed that rings A and B of
CA4 could be similarly accommodated in the T. thermophila tubulin
structure (Fig 2B). However, the aliphatic linker connecting the two
rings of CA4, which is lined by hydrophobic amino acid side chains
in human tubulin is replaced by polar residues in the case of proto-
zoa tubulin (Fig 2A and B). Since a multiple sequence alignment
indicates that bA250 and bA316 are conserved in all human b-
tubulin isoforms (Appendix Figs S3 and S4), we anticipated that the
two key differences in the colchicine site of protozoan versus
human tubulin (S/A250 and S/A316) would offer the opportunity to
modify CA4 for parasite-specific tubulin binding. To identify candi-
dates that discriminate between protozoan and vertebrate tubulins,
we assessed compounds from a commercially available ligand
library (see methods). We searched for compounds that are similar
to CA4 but which have alterations in the aliphatic linker connecting
their two aromatic rings in CA4 to take advantage of the presence of
the two colchicine-site serine (or cysteine) residues at positions 250
and 316 in protozoan tubulin (Fig 2B and Appendix Fig S4), which
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engage this moiety of CA4. Molecules showing the most favorable
binding poses, as judged by molecular modeling and structural anal-
ysis of the compounds in the T. thermophila tubulin crystal struc-
ture, were selected for in vivo testing (see Fig 2B for an example
and supplemental methods).
Among the various compounds tested, only one compound—
which we dubbed parabulin—inhibited T. thermophila cell growth
(Fig 2C and D). To test whether parabulin can bind to tubulin, we
assessed its activity in vitro on dynamic MTs using our TIRF micro-
scopy reconstitution assay. In contrast to the dynamic periods of
growth and shrinkage observed for T. thermophila MTs (Fig 1C),
the addition of parabulin led to a striking reduction in the numbers
of growth events (Fig 3A). The average number of growth events per
MT seed decreased from 0.15  0.001 to 0.03  0.03 per min. When
rare growth events occurred, no significant differences in growth rate
(control vs parabulin P-value = 0.25) or growth length (control vs
parabulin P-value = 0.15) were observed (Fig 3B–D). In control
experiment, addition of colchicine had little effect on the dynamic
properties of T. thermophila MTs (Fig 3A–D), while parabulin had no
detectable effect on the dynamic properties of porcine brain MTs
(Appendix Fig S1D). These data suggest that parabulin would
sequester protozoan tubulin in a polymerization incompetent state by
binding to its colchicine site and by preventing conformational




Figure 1. Protozoan and human tubulin and microtubule structures.
A Coomassie-stained SDS–PAGE showing purified T. thermophila tubulin.
B A representative cryo-electron micrograph of paclitaxel-stabilized T. thermophila MTs.
C Kymographs obtained by TIRF microscopy showing the dynamics of T. thermophila MTs at the indicated concentrations in µM.
D Plot of T. thermophila MT plus-end growth rates as a function of tubulin concentration. Error bars represent the mean  95% CI. For each concentration, data are
obtained from at least 2 independent experiments (n = 41).
E Cryo-electron microscopy density map of a 14 protofilament, paclitaxel-stabilized T. thermophila MT with pseudo-helical symmetry applied. Left: outside view. The a-
and b-tubulin monomers are shown in surface representation and colored in dark and light gray, respectively. Red arrow shows the location of the seam. Right:
tubulin dimer models fitted into a sliced, transparent and zoomed-in view. The paclitaxel structure in stick representation is highlighted in magenta. Lateral contacts
between protofilaments are indicated in blue (H2-S3 in a2 and b2), red(H1-S2 in a2 and b2), and green (M loop in a1 and b1).
F Cartoon representation of the crystal structures of T. thermophila tubulin-D1 (left) and recombinant H. sapiens tubulin-D1 (right) complexes. Bound nucleotides are
displayed in stick representation, the a- and b-tubulin monomers in dark and light gray ribbons for T. thermophila tubulin and light blue and wheat ribbons for
H. sapiens tubulin, respectively.
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that do take place in the presence of parabulin would therefore repre-
sent the residual unbound polymerization competent tubulin as indi-
cated by similar to native microtubule dynamic properties. Together
with our structural analyses, these results suggest that parabulin is a
protozoan-targeting MT-destabilizing agent.
To assess the potential of parabulin as a bona fide anti-parasitic
agent, we evaluated its effects on cultures of human cells and
growth of the apicomplexan parasite Toxoplasma gondii within
human cells. When subconfluent (proliferating) fibroblasts were
exposed to equivalent concentrations of parabulin or CA4 for 72 h,
parabulin exhibited considerably lower cytotoxicity than CA4
(Fig 4A). CA4 has well-defined anti-mitotic activity due to its disrup-
tion of vertebrate MTs (Mooney et al, 2009). In contrast, parabulin
had little to no effect on fibroblast growth or survival, indicating that
it does not harbor significant cytotoxic activity (Appendix Fig S6A).
Immunofluorescence staining of tubulin in fibroblast monolayers
treated with CA4 or parabulin indicates that unlike CA4, parabulin
does not disrupt the MT cytoskeleton of fibroblasts (Fig EV4). To
evaluate the effect of parabulin on parasite replication, GFP-





Figure 2. Analysis of protozoan–tubulin drug-binding sites.
A T. thermophila tubulin structure highlighting the six distinct drug-binding sites found in mammalian tubulin. Enlargements show differences in the taxane, pironetin,
and colchicine sites between T. thermophila (light grey) and H. sapiens (wheat) tubulin. The three distinct zones of the colchicine site are highlighted by colored
transparent ovals. Amino acid residue differences between human and protozoa tubulin are indicated. Residues are displayed in stick representation and color-coded
accordingly to elements (N, blue; O, red; S, yellow; for human and protozoa, respectively).
B A zoom out of the colchicine site of T. thermophila tubulin showing the atomic arrangement of modeled CA4 (green) and parabulin (yellow).
C Chemical structures of CA4 and parabulin. The two CA4 rings, denoted A and B, are highlighted as well as the linker (yellow).
D Plot showing the time course of T. thermophila cell growth in the presence of CA4 (20 µM) or parabulin (50 µM; error bars corresponding to the standard deviation of
triplicate biological measurements). Control experiments are done with DMSO alone.
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monolayers to allow invasion. After addition of parabulin, there
was a significant reduction in parasite replication compared to
control cultures (Fig 4B). Whereas most parasite vacuoles in control
samples contained 8 or more parasites, meaning that these tachy-
zoites have doubled at least 3 times after invasion (Fig 4B, top),
parabulin-treated samples display vacuoles harboring significantly
fewer parasites, indicating that replication is delayed by 1–3 replica-
tion cycles. We separately assessed whether parabulin treatment
influences host cell invasion (infectivity) using a “red-green/in-out”
assay that distinguishes extracellular and intracellular parasites
(Huynh et al, 2003) and found that parabulin also reduces tachy-
zoite invasion of host cells (Appendix Fig S6B). We used a T. gondii
plaque assay to determine the concentration at which parasite
proliferation is reduced by half (EC50 value); this analysis captures
effects on both invasion and intracellular replication because
plaques arise after several rounds of invasion, replication, and para-
site egress (Ma et al, 2008). When confluent fibroblast monolayers
were infected with tachyzoites and left to grow for seven days, lytic
parasite growth created visible holes in the vertebrate fibroblast
monolayer. Both the plaque numbers and sizes were reduced by
parabulin treatment. Quantification of the plaque area relative to
control samples indicates that the parabulin has an EC50 value of
6.5 µM (Fig 4C). Although parasites do not display visible MT
defects after short-term treatment, when tachyzoites are serially
passaged in parabulin, aberrant progenies accumulate (Fig 4D).
These abnormal forms arise when nuclear division and daughter cell
budding (cytokinesis) are disconnected, such as in the context of,
for example, mutating tubulin (Ma et al, 2007). Taken together,
these results substantiate our drug design strategy and reveal that
parabulin is a specific inhibitor of protozoan MT functions.
Many of the current strategies to develop new therapeutic drugs
to treat parasite infections focus on phenotypic screens to identify
novel anti-parasitic agents (Fernandez et al, 2019). However, since
parasites like Plasmodium develop resistance quickly after introduc-
tion of new therapies (Haldar et al, 2018), targeted strategies are
also required to tackle deadly parasitic infections like malaria.
A B
C D
Figure 3. Parabulin inhibits Tt-MT growth in vitro.
A Plot showing quantification of the T. thermophila MT growth events in TIRF microscopy MT dynamics reconstitution assays in the presence of the indicated drugs.
Error bars represent the mean  95% CI. For each concentration, data are obtained from at least 2 independent experiments. For growth rates and growth lengths,
n = 41 (DMSO), n = 4 (0.04 lM parabulin), and n = 34 (0.04 lM colchicine). Rates were compared using one-way ANOVA with Tukey’s multiple comparison test;
DMSO vs parabulin P < 0001 (****); DMSO vs colchicine P = 0.40 (n.s., not significant).
B T. thermophila MT growth rates in the presence of the indicated drugs (40 lM). Error bars represent the mean  95% CI (n = 4). Rates were compared using one-
way ANOVA with Tukey’s multiple comparison test; DMSO vs parabulin P = 0.25; DMSO vs colchicine P = 0.20 (n.s., not significant).
C T. thermophila steady-state MT length in the presence of the indicated drugs (40 lM). Error bars represent the mean  95% CI. For each concentration, data are
obtained from at least 2 independent experiments. For growth rates and growth lengths, n = 41 (DMSO), n = 4 (0.04 lM parabulin), and n = 34 (0.04 lM
colchicine). Rates were compared using one-way ANOVA with Tukey’s multiple comparison test; DMSO vs parabulin P = 0.15 (n.s., not significant); DMSO vs colchicine
P < 0001 (****).
D Representative kymographs obtained by TIRF microscopy showing the effect of parabulin and colchicine on dynamic Tt-MTs.
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Inhibiting essential parasite pathways using drug formulations
targeting multiple sites on a single, essential parasite protein repre-
sents an attractive approach to controlling these parasitic infections.
Here, we show that it is possible to specifically target parasite tubu-
lin without harming the human host cell. We identified a compound
that specifically alters parasite MTs and inhibits parasite replication
and host cell invasion. Parabulin, which inhibits growth of proto-
zoan MTs, complements the recent identification of a tubulin-
binding compound that selectively promotes growth of Leishmania
and Trypanosoma (kinetoplastid) MTs to specifically inhibit parasite
replication (Ullah et al, 2020). By pairing structural and biochemical
studies with drug design and Toxoplasma assays, we confirm the
potential of rationally developed MT-targeting agents as anti-
parasitic treatments. Moreover, our structural information offers a
unique basis to develop additional selective ligands that bind to
distinct sites on parasite tubulins.
Materials and Methods
Tetrahymena thermophila culture and tubulin purification
Tetrahymena thermophila cells (strain SB210, Cornell University,




Figure 4. Parabulin inhibits parasite invasion and replication.
A Evaluation of vertebrate cell toxicity using the MTT assay which detects metabolic activity proportionate to the number of viable cells in a sample. The absorbance
measurements for all treatment conditions were normalized to the null control value which is set to 100% growth. Subconfluent human fibroblasts were used to
visualize potential compound effects during proliferation. The results represent the average of 9 readings (3 biological replicates with 3 technical replicates of each
treatment)  standard error of the mean.
B Replication of GFP-expressing T. gondii tachyzoites in individual intracellular vacuoles can be followed by live cell imaging. Since vacuoles containing more than eight
tachyzoites are not always easy to score, we tallied vacuoles above eight as being 8+ in size. At 36 h, both null and vehicle control samples show most vacuoles
harbor eight or more tachyzoites (three or more doublings). Vacuoles in parabulin-treated cultures contain significantly fewer parasites, indicating that replication is
slowed. The graph shows three biological replicates with values normalized to 100% for each condition and each replicate, error bars represent standard error of the
mean between experiments.
C The parabulin EC50 value for T. gondii growth was determined using a plaque assay to measure a reduction in plaque area relative to control conditions. Error bars
represent standard error of the mean. The results represent the average of 18 readings (6 biological replicates with 3 technical replicates of each treatment) 
standard error of the mean.
D Phase contrast of extracellular parasite cultures. Serial passage of T. gondii in 40–80 lM parabulin induces accumulation of aberrant tachyzoite forms. These arise
with MT defects that disconnect coordinated nuclear division and daughter cell budding.
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media (Sequestrene Proteose Peptone: 1% protease peptone, 0.1%
yeast extract, 0.2% glucose, 33 lM FeCl3, and 1% Penicillin/Strep-
tomycin/Amphotericin B Mix from PAN Biotech). Cells were
collected by centrifugation for 15 min at 6,000 g, flash–frozen, and
stored at 80°C.
Each tubulin purification used 48 to 72 l of cells. The cell pellets
were resuspended in a final total volume of 250 ml of PME buffer
(0.1 M PIPES pH 6.9, 1 mM MgCl2, 1 mM EGTA) plus protease inhi-
bitor (0.5 mM phenylmethylsulfonyl fluoride and cOmpleteTM
Roche), and sonicated on ice for 30 min (2 s ON, 2 s OFF, 30%
amplitude macrotip VibraCell). The sonicated cells were cooled on
ice for an additional 30 min before being spun down at 20,000 g for
40 min at 4°C. The resulting clarified supernatant was filtered
through a 0.45-micron filter then loaded onto a 5-ml HiTrap DEAE
Sepharose FF (GE Healthcare). The column was washed with 2
volumes of PME buffer followed by 4 volumes of PME buffer
containing 100 mM KCl and 0.25 M glutamate. Bound tubulin was
eluted with 2 volumes PME buffer containing 300 mM KCl and
0.75 M glutamate. An assembly-competent tubulin fraction was
purified by a cycle of polymerization–depolymerization: After
elution from the DEAE column, 10 mM MgCl2, 2 mM GTP, and 8%
DMSO (final concentration) were added to the pooled tubulin which
was incubated at 37°C for 1 h. After spinning at 50,000 g for 30 min
at 37°C, the supernatant was removed, and the polymerized tubulin
pellet was resuspended in 100 ll cold PME buffer. The tube was
incubated on ice for 15 min and then transferred into ice-cold water
for sonication 1 min 5 s ON 2 s OFF 30% amplitude with a macrotip
(VibraCell). The tubulin was spun down once more at 50,000 g for
20 min at 4°C. The resulting supernatant consisted of pure TtTubu-
lin which was used for crystallization and other biochemical assays.
Labeling of tubulin for TIRF experiments
We added 5 ll of 1 M MgCl2, 20 ll of 100 mM GTP, and 1 ml glyc-
erol to 40 mg of purified TtTubulin (2 ml volume) and incubated it
for 1 h at 37°C. Polymerized tubulin was layered on top of 1 ml of
warm (37°C) High pH Cushion (0.1 M NaHEPES, pH 8.6, 1 mM
MgCl2, 1 mM EGTA, 60% (v/v) glycerol) and spun at 70,000 g for
20 min at 35°C. The supernatant above the cushion was aspirated
and the supernatant–cushion interface rinsed twice with warm
labeling buffer (0.1 M NaHEPES, pH 8.6, 1 mM MgCl2, 1 mM EGTA,
40% (v/v) glycerol). The pellet was resuspended in 500 ll of warm
labeling buffer. Alexa Fluor 488 Carboxylic Acid was then added to
the mixture in a 10-fold molar excess. The labeling reaction was
incubated for 10 min at 37°C before addition of 500 ll of Quench
(2× BRB80, 100 mM K-Glutamate, 40% (v/v) glycerol) with a
further 5-min incubation. In order to remove free dye, the quenched
labeling reaction was layered onto 1 ml of Low pH Cushion (60%
(v/v) glycerol in 1× BRB80) and spun at 70,000 g for 20 min at
35°C. The labeled tubulin pellet was resuspended in 400 ll of ice-
cold 1× BRB80 and incubated on ice for 30 min. Depolymerized
labeled tubulin was spun at 70,000 g for 10 min at 4°C. The active
fraction of 488-Tt Tubulin was recovered by an additional cycle of
polymerization–depolymerization. We added 4 mM MgCl2, 1 mM
GTP, and half the volume of glycerol to the cold spin supernatant
and incubated it for 30 min at 37°C. The polymerization reaction
was layered on 1 mM Low pH Cushion, and the microtubules spun
down at 70,000 g for 20 min at 37°C. The supernatant was
aspirated, and the pellet washed with 1 ml of warm 1× BRB80 to
remove any residual glycerol. The pellet was resuspended in 100 ll
ice-cold 1× BRB80 and incubated on ice for 30 min. A final spin at
70,000 g for 10 min at 4°C removed any aggregated tubulin. At this
time, the supernatant was recovered, the tubulin concentration
determined and the 488-TtTubulin was concentrated to 3 mg/ml,
aliquoted in 5 ll aliquots, and flash-frozen in liquid nitrogen.
Crystallization and structure solution
Darpin 1 was produced as previously described (Sharma et al,
2016). HsTbIIID1 was crystallized as described previously (La Sala
et al, 2019). The TtTD1 complex was obtained by diluting pure
tubulin to 1 mg/ml in water and 1 mM GTP with subtilisin (Sigma)
added to a 1/100 weight ratio. After a 45-min incubation at 25°C,
the reaction was stopped with PMSF (2 mM final concentration)
and MgCl2 was added to a final concentration of 1 mM. After
40 min on ice, the mixture was spun down at 70,000 g for 30 min at
4°C. Darpin 1 was added in a 1:1 molar ratio, and the complex was
concentrated to 40 mg/ml. Crystals grew overnight in hanging drop
vapor diffusion at 20°C in 0.2 M sodium sulfate, 10% DMSO, and
18% PEG 3350.
X-ray diffraction data were collected at the PXIII beamline of the
Swiss light source. Data were processed using XDS software package
(Kabsch, 2010a, b). HsTbIIID1 crystallized in the space group P1211
with a single molecule in the asymmetric unit. Structure solution
was performed by the molecular replacement method using a previ-
ously published TD1 structure after removing all the ligands and
solvent molecules (PDB ID 4DRX) and the program PHASER in the
PHENIX software package (Zwart et al, 2008). TtTD1 crystallized in
the space group P1211 with two molecules of TtTD1 in the asym-
metric unit. The TtTD1 structure was solved by molecular replace-
ment using the TbIIID1 structure without the ligand as a model.
Nucleotides were added to the model using eLBOW in PHENIX, and
the structure was further refined through iterative rounds of model
building in Coot (Emsley & Cowtan, 2004; Emsley et al, 2010) and
PHENIX. The quality of the structure was assessed with MolProbity
(Chen et al, 2010). Data collection and refinement statistics are
presented in Appendix Table S2. Figures were prepared using
PyMOL (The PyMOL Molecular Graphics System, version 1.4.1.
Schrödinger).
Cryo-EM specimen preparation and data acquisition
A 4 ll of paclitaxel-stabilized Tt-MT at 10 lM was applied to a
glow-discharged C-flat 2/2–4C grid (Protochips, Morrisville, NC) at
room temperature and incubated on the grid for 1 min. The grid
was subsequently blotted and plunge-frozen using a Vitrobot Mark
IV (Thermo Fisher Scientific) with the following setting: blot force
of 5, blot time of 5 s, humidity of 100%, and temperature of 22°C.
Micrographs of paclitaxel-stabilized Tt-MT were manually collected
using a Tecnai Polara microscope (Thermo Fisher Scientific) operat-
ing at 300 kV, with a K2 summit direct electron detector (Gatan,
CA, USA) and a quantum post-column energy filter (Gatan) in zero-
loss imaging mode. A nominal defocus range of 1.0–3.5 lm and a
final pixel size of 1.39 A were used. The total dose was 45 e-/A2
over 50 frames, with the detector operating in counting mode at a
rate of 5.8 e-/pixel/s.
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For the Tt-MT samples used for 3D structure determination, a
purified recombinant kinesin motor domain (Plasmodium berghei
kinesin-8B motor domain; PBANKA_0202700, residues 760–1,130)
was bound to the MTs to act as a fiducial to facilitate image process-
ing. Thus, after incubation of 10 lM paclitaxel-stabilized Tt-MT
MTs on a C-flat grid for 1 min, 3.5 ll of MTs were removed by
pipetting to leave a thin film, followed by application of 3.5 ll of 50
uM purified kinesin-8B motor domain, followed by 30 s incubation
at room temperature. 3.5 ll of sample was removed from the grid
by pipetting, followed by a second application of 3.5 ll of 50 lM
kinesin, a further 30 s incubation, and the grid was then vitrified
using the conditions above. The kinesin was prepared as follows.
The P. berghei kinesin-8B motor domain in the pNIC28Bsa4 vector
encoding an N-terminal His6 tag was transformed into E. coli BL21
(DE3)* competent cells (Invitrogen), bacterial cultures were grown in
large scale to OD 0.6–0.8 at 37°C and recombinant protein expression
was induced with 20 lM IPTG at 20°C for 12 h. Pelleted cells were
resuspended in lysis buffer (20 mM Tris–HCl pH 7.5, 500 mM NaCl,
5 mM MgCl2) with EDTA-free protease inhibitor (Roche), followed by
sonication for 30 min and then centrifugation at 50,000 g, 4°C for
30 min. The His6-tagged kinesin was purified using immobilized
metal affinity chromatography (IMAC), followed by incubation with
TEV protease for 12 h at 4°C to remove His6 tag. The protein was
exchanged into low-salt buffer (20 mM Tris–HCl pH7.5, 100 mM
NaCl, 5 mM MgCl2) and subjected to a further reverse-IMAC step,
followed by ion exchange (HiTrap Q HP IEX column, GE Healthcare)
to remove any residual bacterial proteins, which bind to the Q
column. The Q column flow-through was aliquoted and snap-frozen
for further use. Before cryo-EM sample preparation, the purified
motor domain was buffer exchanged into 80 mM PIPES pH 6.8,
1 mM MgCl2, 1 mM EGTA, and incubated with apyrase (Sigma) for
10 min at room temperature to remove nucleotides.
A total of 6,188 micrographs were collected using a Titan Krios
(Thermo Fisher Scientific) with a K2 summit direct electron detector
(Gatan, CA, USA) and a quantum post-column energy filter (Gatan)
operating in zero-loss imaging mode. The microscope was operated
at an accelerating voltage of 300 kV with nominal magnification of
130 K and pixel size of 1.05 A. Using EPU (Thermo Fisher Scientific),
32 frames for each movie were collected with 8 s exposure time,
47.112 e/A2 electron exposure, 1.472 e/ A2 frame dose, and 6.794
e-/pixel/s dose rate. The defocus range was from 0.5 to 2.5 lm.
Image processing and 3D reconstruction
Frames 2 to 16 were motion-corrected using MotionCor2 (Zheng
et al, 2017). The parameters of the contrast transfer function (CTF)
for each micrograph were determined using CTFFIND4 (Rohou &
Grigorieff, 2015). About 76,240 particles with box size of 644*644
pixels and non-overlapping region of 78 pixels were picked using
EMAN2 (Tang et al, 2007). Protofilament (pf) number determination
and global refinement were done using multi-reference alignment in
EMAN1 (Ludtke et al, 1999; Tang et al, 2007). All 14 pf particles
were merged for further data processing. Seam search and local
refinement with HP symmetry were performed in FREALIGN v9
(Lyumkis et al, 2013) as described previously (Alushin et al, 2014;
Zhang & Nogales, 2015). The pseudo-helical symmetry parameters
of MTs were measured from the asymmetric (C1) reconstruction of
the same dataset followed by “hsearch” script in IHRSR package
(Egelman, 2010). No B factor was applied to the final reconstruc-
tion. The FSC was calculated for the whole map reconstructed from
the odd and even half of the datasets using a cylindrical, soft-edge
Gaussian mask with an inner radius of 75 A and outer radius of
145 A (Appendix Fig S10A).
Microtubule structure modeling and refinement
A porcine tubulin dimer model (from PDB ID 6EW0) was fitted into
the electron density of T. thermophila microtubules using fitmap
command in UCSF Chimera (Pettersen et al, 2004). The fitted model
was subsequently changed to T. thermophila tubulin sequence using
COOT. Model building and refinement were performed as described
previously (Eshun-Wilson et al, 2019). Briefly, we built a central ⍺b
tubulin dimer in COOT and refined a 4X3 lattice of tubulins. Refine-
ment was performed by iterative cycles of phenix.real_space_refine
in PHENIX (Afonine et al, 2018) and manual model building in COOT
(Appendix Table S1 and Fig S10B and C).
Modeling and drug design
In order to model the colchicine-bound conformation, TtTD1 struc-
ture was superimposed to the colchicine-bound bovine tubulin
model (PDB ID 4O2B) in COOT. The amino acid residues and
secondary structure elements of b-tubulin were modeled manually
using Coot to mimic the colchicine-bound conformation of Tt Tubu-
lin (Tt–TD1c). CA4 was manually docked in the TtTD1c using COOT
and the ligand-bound pocket was energy-minimized using MAB
forcefield in Moloc (Gerber Molecular Design, Switzerland, (Gerber
& Muller, 1995)). The modeled CA4-TtTD1 structure was used for
further drug optimization using COOT. We manually searched the
Enamine REAL database (Enamine Ltd.) using CA4 as a search
query and selected compounds having the desired linkers.
Compounds were selected by modeled in the TtTD1c structure in
COOT, followed by binding pocket minimization in Moloc.
Compounds showing favorable binding poses (by visual inspection
in Coot) were selected and purchased from Enamine.
Tetrahymena growth inhibition assay
For the T. thermophila growth inhibition assay, fresh cultures were
prepared by inoculating 250 ml of SPP growth medium containing
Pen/Strep antibiotics with 200 ll of a stock culture, followed by
incubation at 30°C and 100 rpm shaking. Actively growing cells at
cell density of 100,000 cells/ml were distributed at 100 ll volume
into a microtiter plate. A mosquito automatic pipetting robot (SPT
Labtech) was used to add 0.1 ll volumes of drugs or DMSO control
to each well, and samples were evaluated in triplicate. The micro-
titer plate lids were treated with 0.1% Triton X-100 in 20% ethanol
to prevent condensation. Covered plates were incubated at 30°C for
72 h; absorbance at 600 nm was read every 30 min by a PheraStar
FSX plate reader (BMG LABTECH). Data were plotted using Data-
Graph software (Visual Data Tools).
Microtubule growth reconstitution assay
Bright MT seeds were prepared from cytoskeleton porcine tubulin
stocks. Samples contained 1 mg/ml final concentration each of
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unlabeled, X-rhodamine-labeled, and biotin-labeled tubulin in
BRB80 with 0.5 mM GMPCPP. This solution was incubated at 37°C
for 30 min, and then, the seeds were pelleted by centrifugation at
16,000 g for 10 min. Pelleted seeds were resuspended in 40 µl of
BRB80 and used on the day they were prepared.
Flow chambers for TIRF microscopy were prepared on glass
slides with double-sided tape and biotin-PEG coverslips (MicroSur-
faces Inc.). Chambers were first incubated with blocking solution
(0.75% Pluronic F-127, 5 mg/ml casein) for 5 min, then washed
with BRB80-casein (80 mM PIPES, 5 mM MgCl2, 1 mM EGTA,
1 mM DTT, 1 mg/ml casein). 0.5 mg/ml neutravidin was incubated
for 2 min and then excess removed with washes in BRB80-casein.
1:200 diluted GMPCPP seeds were then incubated for 2 min and the
excess washed out again with BRB80-casein. The final assay mix
was prepared in BRB80-casein with an oxygen-scavenging system
(20 mM glucose, 300 lg/ml glucose oxidase, 60 lg/ml catalase),
0.1% methylcellulose, 0.5 mM GTP, and tubulin to the desired final
concentration. The tubulin mix consisted of Alexa488-labeled and
unlabeled tubulin at a ratio of 1:4 for Tetrahymena samples and 1:9
for porcine samples. A range of tubulin concentrations between 2.5
and 5 lM were assessed for Tetrahymena MT dynamics; 3 lM was
identified as a suitable concentration for the porcine tubulin experi-
ments.
To test the effect of parabulin and colchicine (Sigma), 1 ll of
drug was added at the desired concentration to the final assay mix.
As a control, 1 ll DMSO was added in “WT” experiments.
For data collection, an Eclipse Ti-E inverted microscope was used
with a CFI Apo TIRF 1.49 N.A. oil objective, Perfect Focus System,
H-TIRF module, LU-N4 laser unit (Nikon) and a quad band filter set
(Chroma). Temperature was maintained at 35°C using a microscope
incubator (Okolab). Frames were collected every 2 s with 100 ms
exposure for 10 min using a iXon DU888 Ultra EMCCD camera
(Andor) through the NIS-Elements AR Software (Nikon). Illumina-
tion was performed sequentially every 2 s at 561 nm for the X-
rhodamine-labeled GMPCPP seeds and 488 nm to show the
Alexa488-labeled MTs that polymerized. Movies were then analyzed
in Fiji with drift-correction if necessary, using StackReg rigid body
transformation. Kymographs extracted from the movies were used
to calculate growth rate, length, and catastrophe frequency values.
For each condition, data from two or more movies were analyzed.
Tissue culture
Human foreskin fibroblast (HFF) cells were grown in D10+ media
composed of DMEM (Dulbecco’s modified Eagle medium) supple-
mented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1%
penicillin–streptomycin. RH strain (ATCC, #50174) T. gondii tachy-
zoites were serially passaged in confluent HFF cells in T25 flasks.
Immunofluorescence assay
Human foreskin fibroblast cells were seeded onto 12-mm circular
glass coverslips in 6-well dishes 2-4 days prior to assays. These cells
were exposed to DMSO (vehicle control), 40 µM combretastatin A4
or 40 µM parabulin for 20–120 min at 37°C. Samples were fixed
with 4% paraformaldehyde for 10 min, permeabilized with 0.25%
Triton-X in PBS- for 10 min, and blocked for 30 min in 10% BSA in
PBS. Coverslips were stained with a mouse monoclonal anti-tubulin
antibody (Sigma T9026, 1:2,000) for 1 h. After washing in PBS,
coverslips were exposed to goat anti-mouse Alexa Fluor 488
secondary antibody (Invitrogen A28175, 1:4,000) for 1 h. After
washing in PBS, coverslips were briefly rinsed in distilled water and
mounted onto glass slides using VectaShield with DAPI. Images
were collected on a Zeiss Axiovert 200 M, and images were
exported and adjusted in Adobe Photoshop CC 2019.
Toxicity assay
Subconfluent conditions: Approximately 5 x 104 HFF cells were plated
into each well of a 24-well dish and exposed to D10+ media alone or
D10+ with DMSO, combretastatin A4 or parabulin for 3 days. The
plates were processed with the In Vitro Toxicology Assay Kit, MTT
based (Sigma-Aldrich, TOX1), and A570 was measured in a Spec-
traMax I3X plate reader. Exported data were analyzed using Microsoft
Excel. Confluent conditions: Approximately 5 × 104 HFF cells were
plated into each well of a 24-well dish and grown to D10+ media
alone. Once the cells were confluent, they were gently rinsed with
PBS to remove the media and then D10+ with DMSO or parabulin
was added to each well. The plates were processed with the In Vitro
Toxicology Assay Kit, MTT based (Sigma-Aldrich, TOX1), and A570
was measured in a SpectraMax I3X plate reader. Exported data were
analyzed using Microsoft Excel.
Invasion assay
Freshly lysed out RH-GFP parasites (Kim et al, 2001) were filtered
and used to assess HFF monolayer invasion under control and
parabulin-treated conditions using an in–out assay as described by
(Sweeney et al, 2010). Samples were fixed with formyl saline with-
out subsequent permeabilization and stained with an anti-SAG1
monoclonal antibody (Thermo Fisher) detected with an anti-mouse
Alexa 488 secondary antibody. Extracellular, invading, and intracel-
lular parasites were scored from 10 random microscope fields; three
biological replicates with individual technical triplicates were quan-
tified.
Replication assay
Freshly lysed out RH-GFP parasites (Kim et al, 2001) were filtered
and diluted by ¼ in D10+ media. 2 ml of diluted parasite media was
added to each coverslip and parasites were allowed to invade into
the cells for 30 min at 37°C. After this, the cell monolayer was
washed with PBS to remove uninvaded parasites. D10+ media alone
or D10+ with DMSO, 40 µM combretastastin A4, or 40 µM parabulin
was added to the dishes. Actively growing parasites in fibroblasts
were imaged every 12 h over a 48-h period using a Zeiss Axiovert
200 M and Axiovision camera to collect 10 random fields of view
for each condition. Samples were stained with a 1:1,000 anti-SAG1
mouse monoclonal antibody (Thermo Fisher) and detected with a
1:1,000 dilution of a goat anti-mouse Alexa 594 secondary antibody
(Thermo Fisher). Parasite replication states were manually quanti-
fied and tallied from 10 random microscope fields to compare the
proportion of singlets, doublets, quadruplets, and 8+ rosettes. Data
were displayed as the fraction of total vacuoles/field that contains
singlet, doublet, quadruplet, or 8+ numbers. Three biological repli-
cates with individual technical triplicates were quantified.
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Determination of EC50 values
HFF cells (ATCC, #SRC-1041) were grown to confluency in 6-well
dishes and infected with 300 parasites/well. Individual wells were
treated with varying concentrations of parabulin (5-60 µM), and the
plates were left undisturbed for 7 days at 37°C in a humidified 5%
CO2 incubator. After one week, the plates were fixed (100%
methanol, 5 min at room temperature) and a 5× crystal violet histo-
logical stain solution was added to each well. Plaques appear as
irregular clear areas that interrupt the purple-colored host cell
monolayer. Grayscale photographic images of the plates were taken
to allow for differentiation between cells (dark gray) and plaques
(white). ImageJ’s “threshold” functionality was used to calculate
plaque number, average size, and percent total area within that
field. To generate the EC50 curve, normalized % total plaque area
(relative to no drug controls) was plotted versus drug concentration
using GraphPad Prism. The results represent the average of 18 read-
ings (6 biological replicates, each with 3 technical replicates)  stan-
dard error of the mean.
Data availability
Structural data were deposited in the RCSB Protein Data Bank
(www.rcsb.org) with the PDB IDs: 7PJE (https://doi.org/10.2210/
pdb7PJE/pdb) and 7PJF (https://doi.org/10.2210/pdb7PJF/pdb).
Patent: Gaillard N. and Sharma A., Paul Scherrer Institute, “Use of
parabulin for targeting protozoan tubulin for the inhibition of proto-
zoan replication”, EP20200188.
Expanded View for this article is available online.
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